Hyperfine, Inc. (HYPR)
| Market Cap | 66.83M -34.4% |
| Revenue (ttm) | 19.06M +80.0% |
| Net Income | -29.81M |
| EPS | -0.30 |
| Shares Out | 106.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 774,630 |
| Open | 0.6710 |
| Previous Close | 0.6793 |
| Day's Range | 0.6106 - 0.6800 |
| 52-Week Range | 0.6106 - 1.9350 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 2.03 (+221.79%) |
| Earnings Date | Nov 9, 2026 |
About HYPR
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredi... [Read more]
Financial Performance
In 2025, Hyperfine's revenue was $13.56 million, an increase of 5.22% compared to the previous year's $12.89 million. Losses were -$35.57 million, -12.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HYPR stock is "Strong Buy." The 12-month stock price target is $2.03, which is an increase of 221.79% from the latest price.
News
Hyperfine reports Q3 EPS (6c), consensus (8c)
Reports Q3 revenue $6.0M, consensus $5.9M. “Q3 2026 marked the beginning of a new trajectory for Hyperfine (HYPR). We delivered record revenue, gross profit, and gross margin, and for the…
Hyperfine backs FY26 revenue view of $20M-$22M, consensus $20.6M
Management continues to expect net cash burn1 for the full year 2026 to be approximately $26 to $28 million, representing a 10% decline at the midpoint as compared to full…
Hyperfine files $150M mixed securities shelf
17:16 EST Hyperfine (HYPR) files $150M mixed securities shelf
Hyperfine Earnings Call Transcript: Q3 2026
Q3 delivered record $6.0M revenue and 56.7% gross margin, with lower operating loss and cash burn. FY revenue and cash-burn guidance were reaffirmed, while the gross-margin floor rose to 52.5%.
Hyperfine Quarterly report: Q3 2026
Hyperfine has published its Q3 2026 quarterly earnings report on November 9, 2026.
Hyperfine Slides: Q3 2026
Hyperfine has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
Hyperfine, Inc. Reports Third Quarter 2026 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine Registration statement: Registration filing
Hyperfine filed a registration statement on November 9, 2026, providing details about a securities offering with the SEC.
Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine management to meet with B. Riley
Meetings to be held on the West Coast on November 11-13 hosted by B. Riley.
Hyperfine initiated with a Buy at Lucid Capital
Lucid Capital analyst Alex Nowak initiated coverage of Hyperfine (HYPR) with a Buy rating and $2 price target The company’s Swoop system is the first and only commercially available FDA-cleared…
Hyperfine announces CE mark, UKCA approval for Optive AI software update
Hyperfine (HYPR) announced CE mark and UKCA approval for its latest Optive AI software update in Europe, further enhancing the capabilities of the Swoop system and supporting broader adoption across…
Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness
GUILFORD, Conn.--(BUSINESS WIRE)--CE mark and UKCA approvals support Swoop system Model 2 expansion as Hyperfine highlights portable MRI in brain health awareness efforts.
Hyperfine reaffirms FY26 revenue view $20M-$22M, consensus $20.17M
Management continues to expect revenue for the full year 2026 to be approximately $20M-$22M, representing 55% growth at the midpoint as compared to full year 2025.
Hyperfine reports preliminary Q3 revenue $6M, consensus $5.13M
Preliminary, unaudited net cash burn, excluding financing proceeds, for the third quarter of 2026 is expected to be approximately $5.6M, representing a 29% sequential improvement compared to the secon...
Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine appoints Roots as distribution partner for Kuwait, UAE
Hyperfine (HYPR) announced the appointment of Roots Pharmaceutical Co. W.L.L. as its exclusive distribution partner for Kuwait and the United Arab Emirates. Under the agreement, Roots Pharmaceutical w...
Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.
MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award
MENLO PARK, Calif.--(BUSINESS WIRE)--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and ...
Hyperfine completes enrollment of Contrast PMR study
Hyperfine (HYPR) announced that it has completed enrollment of the Contrast PMR study, a multi-center clinical study designed to evaluate the feasibility and visualization benefits of contrast-enhance...
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
GUILFORD, Conn.--(BUSINESS WIRE)--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.
Hyperfine management to meet virtually with BTIG
Medical Technology and Digital Health Analyst Thibault holds a virtual meeting with management on September 18 hosted by BTIG.
Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine announces peer reviewed publication of NEURO PMR study
Hyperfine (HYPR) announced the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging. NEURO PMR, or Neurological Evaluation in the Office with Portable MR, is the first…